Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model

A therapeutic approach to improve treatment outcome of ovarian cancer (OC) in patients is urgently needed. Myxoma virus (MYXV) is a candidate oncolytic virus that infects to eliminate OC cells. We found that in vitro MYXV treatment enhances cisplatin or gemcitabine treatment by allowing lower doses...

Descripción completa

Detalles Bibliográficos
Autores principales: Nounamo, Bernice, Liem, Jason, Cannon, Martin, Liu, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573804/
https://www.ncbi.nlm.nih.gov/pubmed/28875159
http://dx.doi.org/10.1016/j.omto.2017.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573804/
https://www.ncbi.nlm.nih.gov/pubmed/28875159
http://dx.doi.org/10.1016/j.omto.2017.08.002

Ejemplares similares